Phase 4 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 50 or older.
- People who have been diagnosed with age-related macular degeneration (AMD) in one or both eyes.
- People whose affected eye or eyes have a specific type of abnormal fluid layer under the retina (called SHRM) along with a certain type of abnormal blood vessel growth (type 2, or a mix of type 1 and type 2).
- People whose eyes have not previously been treated for this condition and are being treated with a medicine called Faricimab according to its official prescribing guidelines.
- People who agree to take part in the study and sign a consent form.
Who may not be able to join:
- People whose eyes have certain other types of abnormal blood vessel growth (type 1, aneurysmal type 1, or type 3).
- People who have the type 2 abnormal blood vessel growth alongside other eye conditions such as short-sightedness (myopia), inflammation inside the eye, or certain other health conditions affecting the eye.
- People whose eye has clouding or haziness in the normally clear parts of the eye that affect vision.
- People who have other diseases affecting the retina, such as diabetic eye disease, blocked blood vessels in the retina, inflammation in the eye, or any other retinal condition that could affect vision or interfere with study measurements.
- People who have a neurological condition — such as memory or thinking problems, stroke, dementia, Parkinson's disease, anxiety, or schizophrenia — that the study doctor believes could affect safety or interfere with the study.
- People who are currently taking part in, or planning to take part in, any other clinical trial.
- People who are pregnant.
- People who are breastfeeding.
- Women who are able to become pregnant and are unable or unwilling to use a highly effective form of contraception (such as tubal ligation, male sterilisation, contraceptives that stop ovulation, or certain intrauterine devices) for the full duration of the study. For the purposes of this trial, a woman is considered able to become pregnant if she has not gone through 12 or more consecutive months without a period due to menopause, and has not had surgical removal of the ovaries or uterus (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
to assess the resolution of subretinal hyperreflective material (SHRM) at week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.